Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A systematic evaluation of the cucurbit[7]uril pharmacokinetics and toxicity after a single dose and short-term repeated administration in mice

J. Pejchal, P. Jošt, L. Múčková, R. Andrýs, M. Lísa, J. Zdarova Karasova

. 2022 ; 96 (5) : 1411-1421. [pub] 20220226

Language English Country Germany

Document type Journal Article

Grant support
18-08937S Grantová Agentura České Republiky

E-resources Online Full text

NLK ProQuest Central from 2002-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2002-01-01 to 1 year ago
Public Health Database (ProQuest) from 2002-01-01 to 1 year ago

Cucurbit[n]urils are macrocyclic compounds capable of forming host-guest complexes with different molecules. In this study, we focused on cucurbit[7]uril (CB[7]) safety and pharmacokinetics. We investigated CB[7] cytotocixity in human renal cells ACHN using the xCELLigence system. We also determined maximum tolerated doses (MTD) and no observed adverse effect levels (NOAEL) after intramuscular (i.m.), intraperitoneal (i.p.), and intragastric (i.g.) administration in mice using clinical observation, blood biochemistry, and histopathology. At NOAELs, we studied its pharmacokinetics in plasma and kidneys. Finally, we performed a 7 day repeated-dose toxicity study at 50% of NOAEL after i.p. administration, assaying CB[7] concentration in plasma, brain, kidney, and liver; we also assessed the liver and kidney histopathology. In vitro, CB[7] did not show toxicity up to 0.94 mg/mL. MTDs in vivo were set at 300, 350, and 600 mg/kg, and NOAEL were established at 150, 100, and 300 mg/kg after i.m., i.p., and i.g. administration, respectively. Parenteral administration produced tissue damage mainly to the kidney, while i.g. administration caused only minor liver damage. Parenteral CB[7] administration led to fast elimination from blood, accompanied with kidney accumulation; absorption from the gastrointestinal tract was minimal. Short repeated i.p. administration was well tolerated. After initial CB[7] accumulation in blood and kidney, the concentrations stabilised and decreased during the experiment. Approximately 3.6% of animals showed signs of nephrotoxicity. Although CB[7] appears to be a promising molecule, nephrotoxicity may be the most critical drawback of its parenteral use, because the kidney represents the main organ of its elimination.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018507
003      
CZ-PrNML
005      
20220804134822.0
007      
ta
008      
220720s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00204-022-03249-7 $2 doi
035    __
$a (PubMed)35220471
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000322287922 $7 xx0102560
245    12
$a A systematic evaluation of the cucurbit[7]uril pharmacokinetics and toxicity after a single dose and short-term repeated administration in mice / $c J. Pejchal, P. Jošt, L. Múčková, R. Andrýs, M. Lísa, J. Zdarova Karasova
520    9_
$a Cucurbit[n]urils are macrocyclic compounds capable of forming host-guest complexes with different molecules. In this study, we focused on cucurbit[7]uril (CB[7]) safety and pharmacokinetics. We investigated CB[7] cytotocixity in human renal cells ACHN using the xCELLigence system. We also determined maximum tolerated doses (MTD) and no observed adverse effect levels (NOAEL) after intramuscular (i.m.), intraperitoneal (i.p.), and intragastric (i.g.) administration in mice using clinical observation, blood biochemistry, and histopathology. At NOAELs, we studied its pharmacokinetics in plasma and kidneys. Finally, we performed a 7 day repeated-dose toxicity study at 50% of NOAEL after i.p. administration, assaying CB[7] concentration in plasma, brain, kidney, and liver; we also assessed the liver and kidney histopathology. In vitro, CB[7] did not show toxicity up to 0.94 mg/mL. MTDs in vivo were set at 300, 350, and 600 mg/kg, and NOAEL were established at 150, 100, and 300 mg/kg after i.m., i.p., and i.g. administration, respectively. Parenteral administration produced tissue damage mainly to the kidney, while i.g. administration caused only minor liver damage. Parenteral CB[7] administration led to fast elimination from blood, accompanied with kidney accumulation; absorption from the gastrointestinal tract was minimal. Short repeated i.p. administration was well tolerated. After initial CB[7] accumulation in blood and kidney, the concentrations stabilised and decreased during the experiment. Approximately 3.6% of animals showed signs of nephrotoxicity. Although CB[7] appears to be a promising molecule, nephrotoxicity may be the most critical drawback of its parenteral use, because the kidney represents the main organ of its elimination.
650    _2
$a zvířata $7 D000818
650    12
$a heterocyklické sloučeniny bicyklické $x toxicita $7 D006574
650    12
$a imidazolidiny $x toxicita $7 D048289
650    12
$a makrocyklické sloučeniny $x toxicita $7 D047028
650    _2
$a maximální tolerovaná dávka $7 D020714
650    _2
$a myši $7 D051379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jošt, Petr $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Hradec Kralove, Czech Republic
700    1_
$a Múčková, Lubica $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Hradec Kralove, Czech Republic $u Biomedical Research Center, University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Andrýs, Rudolf $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 50003, Hradec Králové, Czech Republic
700    1_
$a Lísa, Miroslav $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 50003, Hradec Králové, Czech Republic
700    1_
$a Zdarova Karasova, Jana $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Hradec Kralove, Czech Republic. zdarova.jana@gmail.com $u Biomedical Research Center, University Hospital, Hradec Kralove, Czech Republic. zdarova.jana@gmail.com
773    0_
$w MED00009265 $t Archives of toxicology $x 1432-0738 $g Roč. 96, č. 5 (2022), s. 1411-1421
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35220471 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134816 $b ABA008
999    __
$a ok $b bmc $g 1822207 $s 1169750
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 96 $c 5 $d 1411-1421 $e 20220226 $i 1432-0738 $m Archives of toxicology $n Arch Toxicol $x MED00009265
GRA    __
$a 18-08937S $p Grantová Agentura České Republiky
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...